Sean Wharton
Overview
Explore the profile of Sean Wharton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
3283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wharton S, Kamran E, Thabane L, Yin P, Christensen R
Clin Obes
. 2024 Dec;
15(2):e12724.
PMID: 39618123
This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real-world practice in Canada. The study was conducted through...
2.
Wharton S, Belloum A, Luckevich M, Kamran E, Luguzis A, Eberg M, et al.
Clin Obes
. 2024 Nov;
15(2):e12720.
PMID: 39582393
This study aimed to describe the characteristics, healthcare resources utilized and costs incurred by adults receiving publicly funded obesity care in Ontario, Canada. People living with obesity who first visited...
3.
Bonder R, Kuk J, Ardern C, Wharton S, Kamran E, Davis C
Appetite
. 2024 Nov;
204:107768.
PMID: 39547531
Background: Food addiction (FA) research has primarily concentrated on binge eating as a symptom of this condition. However, FA may encompass various overeating behaviours, including compulsive grazing - the repetitive...
4.
Jastreboff A, le Roux C, Stefanski A, Aronne L, Halpern B, Wharton S, et al.
N Engl J Med
. 2024 Nov;
392(10):958-971.
PMID: 39536238
Background: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide...
5.
Wharton S, le Roux C, Kosiborod M, Platz E, Brueckmann M, Jastreboff A, et al.
Obesity (Silver Spring)
. 2024 Nov;
33(1):67-77.
PMID: 39495965
Objective: The objective of this study was to describe the rationale and design of two multinational phase 3 clinical trials of survodutide, an investigational glucagon and glucagon-like peptide-1 receptor dual...
6.
Bliddal H, Bays H, Czernichow S, Hemmingsson J, Hjelmesaeth J, Hoffmann Morville T, et al.
N Engl J Med
. 2024 Oct;
391(17):1573-1583.
PMID: 39476339
Background: Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among persons...
7.
Kosiborod M, Platz E, Wharton S, le Roux C, Brueckmann M, Ajaz Hussain S, et al.
JACC Heart Fail
. 2024 Oct;
12(12):2101-2109.
PMID: 39453356
Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The...
8.
Mirzadeh P, Kuk J, Wharton S, Ardern C
Obes Res Clin Pract
. 2024 Oct;
18(5):322-327.
PMID: 39353811
Introduction: Since the adoption of billing codes for obesity, few studies have examined their use in administrative healthcare data. Of those that have, analyses have been limited to examinations of...
9.
Mirzadeh P, Kuk J, Wharton S, Reid R, Ardern C
PLoS One
. 2024 Sep;
19(9):e0311190.
PMID: 39325773
Introduction: The experience of persons with obesity (PwO) in the Canadian healthcare setting has not been widely studied. The objective of this study was to assess care in PwO in...
10.
Bays H, Gonsahn-Bollie S, Younglove C, Wharton S
Obes Pillars
. 2024 May;
10:100105.
PMID: 38774294
[This corrects the article DOI: 10.1016/j.obpill.2022.100044.].